Merck & Company Inc (MRK)vsStevanato Group SpA (STVN)
MRK
Merck & Company Inc
$128.66
+2.56%
HEALTHCARE · Cap: $283.78B
STVN
Stevanato Group SpA
$18.39
-0.27%
HEALTHCARE · Cap: $4.98B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5366% more annual revenue ($65.77B vs $1.20B). MRK leads profitability with a 13.6% profit margin vs 11.7%. STVN appears more attractively valued with a PEG of 3.57. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
STVN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$128.66
$47.70 premium
Margin of Safety
+64.0%
Fair Value
$43.34
Current Price
$18.39
$24.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
2.9% earnings growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : STVN
The primary concerns for STVN are P/E Ratio, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
STVN carries more volatility with a beta of 0.78 — expect wider price swings.
STVN is growing revenue faster at 6.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 46/100). STVN offers better value entry with a 64.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a premier global supplier of advanced drug delivery systems, catering to the pharmaceutical and biotechnology industries with innovative, high-quality glass and polymer packaging solutions for injectable medications. With a strong focus on quality, sustainability, and the integration of cutting-edge technology, the company is strategically positioned to capitalize on the increasing demand within the biopharmaceutical sector. Stevanato's commitment to enhancing the efficiency and reliability of drug administration underscores its potential as a compelling investment choice for institutional investors seeking exposure to healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?